Invention Grant
- Patent Title: RNA formulation for immunotherapy
-
Application No.: US16578601Application Date: 2019-09-23
-
Publication No.: US11559587B2Publication Date: 2023-01-24
- Inventor: Ugur Sahin , Heinrich Haas , Sebastian Kreiter , Mustafa Diken , Daniel Fritz , Martin Meng , Lena Mareen Kranz , Kerstin Reuter
- Applicant: BioNTech SE , TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz gGmbH
- Applicant Address: DE Mainz; DE Mainz
- Assignee: BioNTech SE,TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz gGmbH
- Current Assignee: BioNTech SE,TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz gGmbH
- Current Assignee Address: DE Mainz; DE Mainz
- Agency: Choate, Hall & Stewart LLP
- Agent Brenda Herschbach Jarrell; Michael A. Shinall
- Main IPC: A61K48/00
- IPC: A61K48/00 ; A61K39/00 ; A61K9/127
Abstract:
The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.
Public/Granted literature
- US20200085974A1 RNA Formulation for Immunotherapy Public/Granted day:2020-03-19
Information query
